31 completed. 31 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 31 |
| Phase 3 | 4 | Completed 4 |
Follow Long COVID: new trials by email Literature Review of Long COVID trials Research Report on Long COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 Ketamine only - Long COVID | Phase 2 | Completed | University of Texas at Austin | 20 | 2025-06-05 | 2026-09-17 |
| NE3107 in Adults With Neurological Symptoms of Long COVID NE3107, Placebo - Long COVID | Phase 2 | Completed | BioVie Inc. | 203 | 2025-04-29 | 2026-09-22 |
| Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) Plitidepsin 1.5 mg/day, Placebo, Placebo and Plitidepsin 1.5mg/day - Post COVID-19 Condition, Long COVID Syndrome | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 90 | 2025-02-07 | 2026-10-08 |
| RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 361 | 2024-08-12 | 2026-06-03 |
| RECOVER-SLEEP: Platform Protocol Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 830 | 2024-07-31 | 2026-01-22 |
| RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) Melatonin, Melantonin Placebo, Tailored lighting (TL) Active - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 469 | 2024-07-31 | 2026-07-08 |
| RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care - Long COVID, Long Coronavirus Disease 2019 (Covid19) | Phase 2 | Completed | Kanecia Obie Zimmerman | 200 | 2024-05-08 | 2026-07-31 |
| Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC) Tonabersat, Placebo - Long COVID | Phase 2 | Completed | Inflammx Therapeutics Inc | 16 | 2024-03-12 | 2026-03-06 |
| RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) Ivabradine, Ivabradine Placebo, Coordinated Care - Long COVID, Long Covid19 | Phase 2 | Completed | Kanecia Obie Zimmerman | 181 | 2024-03-11 | 2026-02-20 |
| RECOVER-AUTONOMIC Platform Protocol IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care - Long COVID, Long Covid19 | Phase 2 | Completed | Kanecia Obie Zimmerman | 381 | 2024-03-11 | 2026-08-03 |
| Amantadine Therapy for Cognitive Impairment in Long COVID Amantadine - Long COVID, Post-COVID19 Condition | Phase 2 | Completed | Ohio State University | 64 | 2023-12-07 | 2026-01-27 |
| Nitrite Supplementation in Long COVID Patients 140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK), 210 ml of nitrate-depleted placebo - Long COVID, Cardiorespiratory Fitness | Phase 2 | Completed | VA Office of Research and Development | 17 | 2023-12-01 | 2026-08-26 |
| Study of LAU-7b for the Treatment of Long COVID in Adults LAU-7b for 3 cycles, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles - Long COVID | Phase 2 / Phase 3 | Completed | Laurent Pharmaceuticals Inc. | 272 | 2023-11-15 | 2026-01-06 |
| Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo - Long COVID, PASC Post Acute Sequelae of COVID 19 | Phase 2 | Completed | Bateman Horne Center | 59 | 2023-10-15 | 2025-01-22 |
| RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms Paxlovid, Ritonavir, Nirmatrelvir-matching placebo - Long COVID-19, Long COVID | Phase 2 | Completed | Kanecia Obie Zimmerman | 964 | 2023-07-26 | 2026-03-27 |
| RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control - Long COVID, Long Covid19 | Phase 2 | Completed | Kanecia Obie Zimmerman | 963 | 2023-07-26 | 2025-12-02 |
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions Rintatolimod, Placebo / Normal Saline - Post COVID-19 Condition, Long COVID | Phase 2 | Completed | AIM ImmunoTech Inc. | 80 | 2023-06-30 | 2025-01-22 |
| To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID BC 007 or matching placebo - Long Covid | Phase 2 | Completed | Berlin Cures GmbH | 119 | 2023-06-16 | 2024-11-18 |
| AT1001 for the Treatment of Long COVID Larazotide Acetate, Placebo - Long COVID, Long COVID-19 | Phase 2 | Completed | Massachusetts General Hospital | 107 | 2023-05-31 | 2026-08-18 |
| RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Ibudilast, Pentoxifylline, Placebo - Long COVID, Post COVID Condition | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 460 | 2023-05-31 | 2026-02-23 |
Showing 20 of 31. Sign in to see all of them.
Post-Acute COVID-19 Syndrome (31) · COVID-19 (8) · Mental Fatigue (3) · Parasomnias (3) · Disorders of Excessive Somnolence (2) · Fatigue (2) · Coronavirus Infections (1) · Infections (1) · Post-Infectious Disorders (1) · Postural Orthostatic Tachycardia Syndrome (1) · Xerostomia (1)
Chronic Disease (31) · Coronaviridae Infections (31) · Disease Attributes (31) · Lung Diseases (31) · Nidovirales Infections (31) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Pneumonia (31) · Pneumonia, Viral (31) · RNA Virus Infections (31) · Respiratory Tract Diseases (31) · Respiratory Tract Infections (31) · Virus Diseases (31) · Coronavirus Infections (30) · Infections (30)
Ritonavir (4) · Immunoglobulins, Intravenous (2) · Ivabradine (2) · Melatonin (2) · Modafinil (2) · Sugars (2) · nirmatrelvir (2) · nirmatrelvir and ritonavir drug combination (2) · solriamfetol (2) · Amantadine (1) · DMAC2L protein, human (1) · Fenretinide (1) · Fluvoxamine (1) · Lithium (1) · Low-Level Light Therapy (1)
Kanecia Obie Zimmerman (5) · Duke University (3) · AIM ImmunoTech Inc. (1) · Bateman Horne Center (1) · Berlin Cures GmbH (1) · BioVie Inc. (1) · Bod Australia (1) · Cellular Sciences, inc. (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Harlan M Krumholz (1) · Inflammx Therapeutics Inc (1) · Karolinska Institutet (1) · Laurent Pharmaceuticals Inc. (1) · Massachusetts General Hospital (1) · Ohio State University (1)
United States (23) · Canada (2) · Spain (2) · Austria (1) · Brazil (1) · Finland (1) · Germany (1) · Norway (1) · Puerto Rico (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Christina Barkauskas, MD (3) · Cyndya Shibao, MD (3) · Pam Taub, MD (3) · Peter Novak, MD (3) · Susan Redline, MD MPH (3) · Tae Chung, MD (3) · Christopher Grainger, MD (2) · Akiko Iwasaki, PhD (1) · Andrew I Schamess, MD (1) · Angela M Cheung, MD,PhD (1) · Axel Mescheder, Dr. (1) · Christopher Granger, MD (1) · Daniel E Forman, MD (1) · David R Strayer, MD (1) · Elizabeth Iveson (1)
PMID 41720282, PMID 35059791, PMID 38848477, PMID 39356507, PMID 40188838, PMID 40810942, PMID 41625963, PMID 42498469, PMID 42673984
I21RX004409 (1), UL1TR001412 (1)